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The members of the Cas protein family (p130Cas/
BCAR1, Nedd9/HEF1, EFS and CASS4) are scaffold
proteins required for the assembly of signal
transduction complexes in response to several stimuli,
such as growth factors, hormones and extracellular
matrix components. Given their ability to integrate
and coordinate multiple signalling events, Cas proteins
have emerged as crucial players in the control of
mammary cell proliferation, survival and differentiation.
More importantly, it has been found that alterations of
their expression levels result in aberrant signalling
cascades, which promote initiation and progression
of breast cancer. Based on the increasing data from
in vitro, mouse model and clinical studies, in this review
we will focus on two Cas proteins, p130Cas/BCAR1 and
Nedd9, and their coupled signalling pathways, to
examine their role in mammary cell transformation and
in the acquirement of invasiveness and drug resistance
of breast cancer cells. p130Cas/BCAR1 and Nedd9 in the normal
mammary epitheliumIntroduction
Mammary gland development is the result of coordinated
actions of hormones, growth factors and extracellular
matrix signalling pathways. Not surprisingly, deregulation
of proteins acting at various points within these pathways
can contribute to the onset and progression of breast can-
cer. Cas proteins serve as scaffolds to regulate the assem-
bly of intracellular signalling complexes downstream of
numerous receptors, such as growth factor and hormone
receptors as well as integrins. Thus, they play a key role
in integrating multiple signalling networks, which to-
gether ultimately govern cell survival, proliferation and
migration [1].
The Cas family comprises four members: p130Cas/
BCAR1 (p130 Crk-associated substrate; also known as
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regulated 9; also called Human enhancer of filamentation
1 (HEF-1) or Cas-L), EFS (Embryonal Fyn-associated sub-
strate) and CASS4 (Cas scaffolding protein family member
4). These proteins have a similar structure, which is char-
acterized by the presence of multiple protein interaction
domains and several tyrosine and serine phosphorylation
motifs [2] (Figure 1).
Over the past decade, p130Cas/BCAR1 and Nedd9
have emerged as key players in the control of many differ-
ent aspects of mammary gland biology, including mam-
mary epithelial cell homeostasis and mammary tumour
cell behaviour. More interestingly, despite their high simi-
larity, they regulate these processes through both distinct
and overlapping mechanisms.
In this review, we summarize and discuss the most
recent findings regarding the role of p130Cas/BCAR1
and Nedd9 in the normal mammary epithelium and in
different breast cancer subtypes.Several studies have shown that, in normal human breast
tissue, both p130Cas/BCAR1 and Nedd9 are mainly
present in the mammary epithelium rather than in stro-
mal cells, although at relatively low levels and with a het-
erogeneous expression pattern [3-6]. Even if detected in
all the distinct epithelial cell populations, p130Cas/BCAR1
expression is highly enriched in the basal compartment of
the mouse mammary epithelium [4]. Similarly, Nedd9 is al-
most exclusively expressed in basal cells in the normal hu-
man mammary epithelium [7]. During late pregnancy and
lactation p130Cas/BCAR1 is down-regulated [4], whereas
the expression of Nedd9 has never been investigated at
different stages of mammary gland development.
The regulation of p130Cas/BCAR1 levels is crucial for
proper mammary morphogenesis and tissue homeostasis.
Over-expression of p130Cas/BCAR1 enhances mammary
branching morphogenesis in vivo during puberty as well
as ex vivo upon stimulation with either epidermal growth
factor or fibroblast growth factor [3,8]. Moreover, in three-
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Figure 1 p130Cas/BCAR1 and Nedd9 structural features and main interacting proteins. Schematic representation of Cas protein main
domains: an amino-terminal SH3 domain followed by a proline-rich region (PRR), a substrate domain (SD), a serine rich region (SRR), and a
carboxy-terminal domain (CT). The main proteins whose interaction has been demonstrated for both p130Cas and Nedd9 are indicated in black,
the interactors specific for p130Cas are in red and those specific for Nedd9 are in green. Noteworthy, p125FAK binds to the SH3 domain while
the Src family kinases bind to the CT domain. The substrate domain with the multiple YxxP motifs represents the site where Src family kinases
extensively phosphorylate Cas proteins.
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of acini with a filled lumen [9]. Similar defects in lumen
clearance can be evoked in primary mouse mammary ex-
plants when p130Cas/BCAR1 over-expression is specific-
ally combined with epidermal growth factor and oestrogen
treatment [8]. These indications for p130Cas having a
role as a positive regulator of mammary cell growth
are strengthened by the fact that in vivo over-expression
of p130Cas/BCAR1 causes extensive hyperplasia through-
out mammary gland development, delayed involution at
the end of lactation, along with persistent proliferation,
decreased apoptosis and hyper-activation of Src, Erk1/2
and Akt signalling pathways [3].
A likely explanation for the hyper-proliferative pheno-
type associated with high p130Cas/BCAR1 levels might
be the expansion of the progenitor cell population that
occurs following p130Cas/BCAR1 over-expression [4].
Up-regulation of p130Cas also impairs the ability of mam-
mary luminal progenitors to differentiate in response to
lactogenic stimuli and shifts their commitment towards
the basal cell fate [4]. Remarkably, these alterations in the
mammary progenitor cell behaviour depend on the abnor-
mal activation of the c-Kit tyrosine kinase receptor, thus
revealing a novel function of this receptor in the control
of mammary cell differentiation [4].
The consequences of p130Cas/BCAR1 depletion in vivo
in the mammary epithelium remain to be understood.
Transgenic mice expressing the constitutively phosphory-
lated substrate domain (SD) of p130Cas/BCAR1 (MMTV-
Src*/SD p130Cas), which has been reported to act as a
p130Cas/BCAR1 dominant-negative mutant in vitro, do
not exhibit any gross morphological alterations of the
mammary gland [10]. However, the Src*/SD p130Cas mu-
tant does not appear to effectively inhibit endogenous
p130Cas/BCAR1 in vivo. Nevertheless, previous studiessuggest that p130Cas/BCAR1 is required for mammary
epithelial cells to survive and grow in vitro [9].
Lack of Nedd9 does not significantly affect mammary
gland development [11], but whether p130Cas/BCAR1
might be able to compensate for Nedd9 deficiency remains
to be investigated. Yet, more recently, it has been shown
that in NEDD9-null mammary glands, the frequency of
luminal progenitors is reduced, while the basal epithelial
cell population is not altered [12]. However, although
NEDD9-null mammary luminal progenitors show altered
expression of genes involved in mitosis, replicative stress
and centrosome maturation, no defect in their ability to
grow in vitro has been observed. This finding, together
with the selective expression of Nedd9 in basal cells re-
ported by Bruna and colleagues [7], suggests that the
effects of Nedd9 depletion in the luminal cell pool
in vivo may be non-cell autonomous effects.
p130Cas/BCAR1 and Nedd9 signalling in breast
cancer: from cell transformation to tumour cell
dissemination
The relevance of the adaptor proteins p130Cas/BCAR1
and Nedd9 in breast cancer has been highlighted by nu-
merous in vivo and in vitro studies. Both p130Cas/BCAR1
and Nedd9 are abundantly expressed in human breast
tumours and breast cancer cell lines [3,5,6,13].
In particular, p130Cas/BCAR1 protein expression has
been found markedly increased in a large subset of
human breast tumours but with no correlation with
tumour size or lymph node status. In spite of this, in pa-
tients with primary breast cancer, high BCAR1/p130Cas
levels are associated with poor relapse-free survival and
poor overall survival [13,14]. Moreover, up-regulation of
p130Cas/BCAR1 in benign breast lesions indicates that
its over-expression may occur early during mammary
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over-expressed in human breast cancers with respect to
normal tissue. Specifically, Nedd9 expression positively
correlates with a series of adverse prognostic markers,
including high tumour grade [6] and metastatic dis-
ease [5,15].
The mechanisms underlying the up-regulation of
p130Cas/BCAR1 and Nedd9 in breast cancer are still
largely unknown. However, as a concomitant increase of
protein and mRNA levels has been reported [3,6], alter-
ations in their transcription and/or mRNA stability may
contribute to deregulating the expression of these two
genes in mammary tumours. To date, several signalling
pathways relevant to breast cancer aetiology, including
transforming growth factor (TGF)-beta, progesterone
and hypoxia signalling, have been found to positively
regulate Nedd9 mRNA expression [2], but less is known
about the transcriptional control of p130Cas/BCAR1.
In breast cancer cells, BCAR1 transcription is directly
activated by the early growth response protein 1
(EGR1) in response to phorbol esters, but the pres-
ence of putative binding sites for additional transcrip-
tion factors, such as NF-kB, p53 and HIF, in the promoter
region [16] points to a more complex control of BCAR1
gene expression.
In the absence of an oncogenic hit, over-expression of
either p130Cas/BCAR1 or Nedd9 is not sufficient to trigger
mammary cell transformation. Nevertheless, up-regulation
of these two Cas proteins seems to represent a convenient
means for breast cancer cells to concomitantly boost
multiple signalling pathways useful for tumour growth
and invasion. Alternatively, increased Cas levels skew
signalling cascades towards the preferential activation of
specific downstream effectors.
For instance, high levels of p130Cas/BCAR1 in mam-
mary epithelial cells subvert the function of TGF-beta
from a negative regulator of tumour formation to a pro-
moter of growth and dissemination. Elevated expression of
p130Cas/BCAR1 diminishes the ability of TGF-beta to
activate Smad2/3, but strengthens its coupling to p38
mitogen-activated protein kinase (p38 MAPK), thus ren-
dering mammary cells resistant to TGF-beta-induced
growth arrest. On the other hand, depletion of p130Cas/
BCAR1 expression in transformed mammary cells increases
the activation of Smad2/3 and suppresses their ability to
invade in response to TGF-beta [9].
The involvement of p130Cas/BCAR1 in numerous
pathways driving mammary cell transformation is due,
at least in part, to its function as a mediator of integrin-
dependent signalling. Adhesion to the extracellular matrix
induces p130Cas/BCAR1 phosphorylation and association
with Src and focal adhesion kinase (FAK), which in turn
promote survival signalling and activation of the cellular
migration machinery [1,2].Disruption of the interaction between p130Cas/BCAR1
and FAK is sufficient to inhibit mammary tumourigenesis
driven by the polyoma middle T oncogene (PyMT) [17].
Moreover, activating mutations in the Ras or phosphoinosi-
tide 3-kinase (PI3K) pathway do not overcome the require-
ment of a functional p130Cas/FAK signalling complex for
the survival and growth of human breast cancer cells [17].
A recent study shows not only that p130Cas/BCAR1 is
necessary for Src-dependent mammary cell transform-
ation but also that the interplay between p130Cas/BCAR1
and Src is strictly controlled by the E3 ubiquitin-ligase
Cullin 5 (Cul5). Src-mediated phosphorylation of p130Cas/
BCAR1 at specific tyrosine residues is responsible for Cas
binding to the Cul5 adaptor SOCS6 and its consequent
ubiquitylation by Cul5. Notably, loss of Cul5 results in
p130Cas protein stabilization and facilitates the transform-
ation of mammary epithelial cells by Src [18].
The ability of p130Cas/BCAR1 to control the remodel-
ling of the actin cytoskeleton represents a mechanism
commonly used to induce migration of breast cancer cells.
For example, the enzyme lysyl oxidase (LOX) confers a
motile phenotype on breast cancer cells by facilitating the
formation of a p130Cas/Crk/DOCK180 complex, which
sustains Rac activity and subsequent actin polymerization
[19]. Conversely, the LOX pro-peptide (LOX-PP), which is
released during the maturation of the pro-LOX enzyme,
reduces breast cancer cell motility by attenuating phos-
phorylation and activation of p130Cas/BCAR1 [20].
Additional mechanisms that implicate p130Cas/BCAR1
in breast cancer invasion have been described. Tumour
invasiveness often requires epithelial-mesenchymal transi-
tion, during which cells lose adhesions to their neighbours
and become more motile. The link between p130Cas/
BCAR1 and epithelial-mesenchymal transition is suppor-
ted by the role of p130Cas/BCAR1 in the control of breast
cancer cell plasticity. In fact, in the aggressive A17 mouse
mammary tumour cells, p130Cas/BCAR1 silencing in-
duces loss of mesenchymal features and acquirement of
epithelial-like traits, including the re-expression of the
cell-cell adhesion molecule E-cadherin. The mechanism
whereby p130Cas/BCAR1 determines a mesenchymal and
invasive phenotype resides in its capacity to positively
regulate the expression of cyclooxygenase-2 in a Src- and
Jnk-dependent manner [21]. Furthermore, in human mam-
mary epithelial cells both p130Cas/BCAR1 and Nedd9
promote, via Src, removal of E-cadherin from the plasma
membrane and its lysosomal degradation [22].
The first direct in vivo evidence for a role of Nedd9 in
mammary tumourigenesis comes from the study of the
effects of NEDD9 gene ablation in the MMTV-PyMT
mouse model [11]. This study revealed that depletion of
Nedd9 impairs mammary tumour development by limit-
ing the activation of multiple pro-oncogenic signalling
proteins, including its binding partners Fak and Src as
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severe down-regulation of FAK activation, lack of Nedd9
results in defective cell spreading and migration and a
greater susceptibility to anoikis [11].
Beyond its function as a mediator of a variety of integrin-
dependent processes, such as cell adhesion, survival and
migration, Nedd9 can further impact on mammary tumour
cell behaviour through its ability to directly activate the
mitotic regulatory kinase Aurora-A (AurA) [23]. In MCF-7
mammary tumour cells, up-regulation of Nedd9 results in
enhanced AurA activity leading to centrosomal and mitotic
spindle abnormalities, whilst a weaker effect can be seen
after changes of p130Cas/BCAR1 expression [23].
In human breast cancer AurA expression is considered
an independent marker of poor prognosis [24] and it has
been recently found that not only does it positively cor-
relate with the expression of Nedd9 but also that co-
expression of these two proteins has a significantly higher
prognostic value [5]. Whilst most invasive mammary car-
cinomas highly express AurA, few have AurA gene ampli-
fication, implying that post-transcriptional mechanisms
may be responsible for the alterations in AurA protein
levels. Interestingly, binding of Nedd9 to AurA protects
AurA from degradation by blocking its association with
the APC/C ubiquitin ligase complex. As a consequence,
Nedd9 overexpression in breast cancer cells leads to AurA
protein stabilization and decreases the efficacy of AurA in-
hibitors [5] (Figure 2). In addition to its role in regulating
the mitotic cell machinery, Nedd9 cooperates with AurAFigure 2 Schematic representation of the mechanisms of Aurora-A kina
mediated by Aurora-A kinase in breast cancer cells. AurA, Aurora-A; CTTNto control actin cytoskeleton dynamics and motility of
breast cancer cells. Nedd9, through activation of AurA,
negatively regulates cortactin (CTTN) acetylation and
favours its binding to F-actin, thus sustaining cell migra-
tion and invasion [25] (Figure 2).
Increased levels of Nedd9 protein significantly correl-
ate with the transition from in situ to invasive mammary
carcinoma [15]. This observation is in line with a novel
function ascribed to Nedd9 at the invasive pseudopodia
of breast cancer cells. Nedd9 is able to direct local
matrix degradation by reducing the levels of TIMP2 on
the cell surface and favouring the activation of MMP14,
MMP2 and MMP9 matrix metalloproteinases [15]. Nedd9
has also been identified as one of the key genes that medi-
ate the switch from cohesive to single cell motility induced
by TGF-beta during breast cancer cell dissemination. Up-
regulation of Nedd9 by TGF-beta is indeed required for
proper actin rearrangements at the leading edge and effi-
cient amoeboid motility of migrating tumour cells [26].
Given the increasing evidence that depletion of Nedd9
drastically reduces migration and invasion of highly
metastatic mammary tumour cells [5,15,25], inhibition
of Nedd9 expression and/or activity represents an attract-
ive strategy to target aggressive breast cancer cells. How-
ever, the complex scenario resulting from Nedd9 depletion
should be taken into account. Indeed, silencing of Nedd9
can also cause centrosomal and spindle defects because
of an abnormal AurA kinase activation [23]. As well,
cells from MMTV-PyMT; NEDD9-null mammary tumoursse regulation by Nedd9 and major effects of Nedd9 up-regulation
, cortactin; Ub, ubiquitin.
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facilitates the selection of cells with a more aggressive
phenotype [27].
The contribution of p130Cas/BCAR1 and Nedd9 to
specific oncogenic pathways in different breast cancer
subtypes is described in detail in the paragraphs below.
p130Cas/BCAR1 and Nedd9 in estrogen
receptor-positive breast cancer
Expression of the oestrogen receptor (ER) in breast can-
cer inversely correlates with poor prognosis. Develop-
ment and growth of ER-positive tumours are strictly
dependent on the activity of ER, which, in addition to its
well-described genomic action as a regulator of tran-
scription, is also able to associate with cytoplasmic
transducer molecules and activate non-genomic intracel-
lular signalling cascades [28].
In ER-positive breast cancer, high levels of p130Cas/
BCAR1 are associated with poor prognosis and a higher
risk of developing resistance to anti-oestrogen therapy
[13,29]. The increased aggressiveness observed for ER-
positive breast cancer expressing high p130Cas/BCAR1
levels may arise from the p130Cas/BCAR1-dependent ac-
tivation of non-genomic ER signalling. Indeed, high levels
of p130Cas/BCAR1 in T47D breast cancer cells promote
the assembly of a multi-protein complex including ERα,
c-Src, and PI3K. In the presence of oestrogen, this ma-
cromolecular complex induces non-genomic ER prolif-
erative signalling through Src and MAPK activation and
the expression of cyclin D1. Conversely, silencing of
endogenous p130Cas/BCAR1 is sufficient to markedly
reduce oestrogen-dependent activation of Src and MAPKs
as well as induction of cyclin D1 [30]. In parallel, in MCF-7
breast cancer cells, exposure to the selective ER modulator
tamoxifen has been found to induce Src-mediated phos-
phorylation of p130Cas/BCAR1, which in turn promotes
the activation of a pro-survival signalling pathway involving
FAK and Akt [31] (Figure 3A).
At present, few data regarding a specific role for Nedd9
in ER-positive breast cancer are available, although, inter-
estingly, its phosphorylation status has been linked to
responsiveness to oestrogens. Indeed, ER-positive breast
cancer cells preferentially express a hypophosphorylated
form of Nedd9 (105 kDa Nedd9) rather than the highly
phosphorylated form (115 kDa Nedd9), which is known to
mediate cell spreading and migration [2]. In MCF7 cells,
oestrogen treatment stabilizes the 105 kDa Nedd9 form
and suppresses the ability of Nedd9 to induce cell spread-
ing, thus suggesting that Nedd9 phosphorylation status
might be an indicator of breast cancer cell motility in
response to oestrogens [32]. However, the specific path-
ways that are activated following oestrogen-dependent
changes of Nedd9 phosphorylation have not been defined
yet (Figure 3A).p130Cas/BCAR1 and Nedd9 in ErbB2 breast cancer
Overexpression of the epidermal growth factor receptor
2 (ErbB2) occurs in approximately 25% of all breast can-
cers and is correlated with disease progression, decreased
survival and metastasis. Such a poor prognosis is a
likely reflection of the biological effects of ErbB2 over-
expression, including increased cellular proliferation,
anti-apoptosis, cell invasiveness and promotion of angio-
genesis [33].
A positive correlation between the expression of BCAR1/
p130Cas and ErbB2 has been found in human breast can-
cers and the co-expression of these two genes is associated
with shorter overall survival and a higher risk of develop-
ing distant metastasis [34]. Moreover, concomitant expres-
sion of p130Cas and ErbB2 proteins is related to a higher
proliferative index [3].
The role of p130Cas/BCAR1 as a mediator of ErbB2
signalling was initially demonstrated in breast cancer cell
lines devoid of ErbB receptors, in which over-expression
of ErbB2 was sufficient to induce cell migration by trig-
gering the coupling between p130Cas/BCAR1 and Crk
[35]. Further in vivo analyses have shown that in the
MMTV-NeuT mouse model of ErbB2 tumourigenesis,
over-expression of p130Cas/BCAR1 accelerates the on-
set of mammary tumours, which are characterized at the
molecular level by increased activation of c-Src and Akt
[3]. Consistently, silencing of p130Cas/BCAR1 is suffi-
cient to impair growth of MMTV-NeuT spontaneous
tumours [36]. Mechanistically, the synergistic action of
p130Cas/BCAR1 and ErbB2 is due to the ability of
p130Cas/BCAR1 to interact with Erb2 and mediate the
assembly of a functional molecular complex consisting
of ErbB2, c-Src, and FAK [36].
p130Cas/BCAR1 cooperates with ErbB2 not only in
mammary cell transformation but also in driving breast
cancer cell migration and invasion and formation of
metastasis [34,36,37]. A recent in vivo study indicates
the interaction between p130Cas/BCAR1 and the FAK-
related kinase Pyk2 is required for ErbB2-transformed
cells to invade and form metastasis [38]. Moreover, in
MCF10A.B2 cells p130Cas/BCAR1 over-expression upon
activation of ErbB2 induces cell invasion by strengthening
ErbB2 downstream signalling and leading to enhanced
Rac1 activation and MMP9 secretion [34,36]. The invasive
phenotype resulting from the concomitant p130Cas/
BCAR1 over-expression and ErbB2 activation relies on a
specific transcriptional program, which includes protein-
coding genes and microRNAs involved in the control of
amino acid synthesis, cell motility, migration, and angio-
genesis [37] (Figure 3B).
The existence of mutual regulation between Nedd9 and
ErbB2 is supported by independent studies showing that
Nedd9 up-regulation increases the levels of ErbB2 mRNA
[39] and, on the other hand, stimulation with the ErbB2
Figure 3 Biological effects and signalling pathways involving p130Cas/BCAR1 and Nedd9 in different breast cancer subtypes.
(A) Estrogen receptor (ER)-positive breast cancer. (B) ErbB2-positive breast cancer. (C) Triple-negative breast cancer. PI3K, phosphoinositide 3-kinase;
SRF, serum response factor; TGF, transforming growth factor.
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[40,41]. The evidence of a functional role for Nedd9 in
ErbB2-dependent tumourigenesis has been provided by
the analysis of MMTV-ErbB2 mice with the genetic dele-
tion of NEDD9, demonstrating that MMTV-ErbB2;
Nedd9-null mice are strongly resistant to tumour for-
mation. The requirement of Nedd9 expression at the
early stages of ErbB2-dependent tumourigenesis re-
flects its role in the control of pre-tumourous luminal
progenitor cell growth. Specifically, in the absence of
Nedd9, MMTV-ErbB2-luminal progenitors exhibit pro-
found defects in the activation of adhesion signalling
pathways together with a markedly reduced proliferative
potential [12].
Since loss of either Nedd9 or p130Cas/BCAR1 impairs
growth of ErbB2 tumours, the full activation of crucial
ErbB2 downstream effectors, such as Src and FAK, may
require the co-expression of Nedd9 and p130Cas/BCAR1,
suggesting that these two Cas proteins cooperate during
early ErbB2 tumourigenesis (Figure 3B).p130Cas/BCAR1 and Nedd9 in triple-negative
breast cancer
Triple-negative breast cancer (TNBC) is an aggressive
breast cancer subtype defined by the lack of ER, progester-
one receptor and human epidermal growth factor receptor
2 (ErbB2). Despite these distinctive histological features,
TNBC comprises a highly heterogeneous group and en-
compasses a number of intrinsic molecular subtypes, most
frequently basal-like and claudin-low [42].
Increasing data indicate that basal-like breast cancer
originates from mammary luminal progenitors [43].
p130Cas/BCAR1 up-regulation is sufficient to confer basal
cell features on luminal progenitors and to impair their
full maturation in response to lactogenic stimuli. These
defects in luminal progenitor differentiation together with
the deregulation of the c-Kit receptor, which result
from p130Cas/BCAR1 over-expression, closely resem-
ble the phenotypes associated with Brca1 deficiency in
the mammary epithelium [43]. Together, these observa-
tions indicate that p130Cas/BCAR1 up-regulation might
Figure 4 Schematic representation of the mechanisms
underlying p130Cas/BCAR1 up-regulation in tamoxifen-resistant
cells and major signalling events in p130Cas/BCAR-dependent
anti-oestrogen resistance. PI3K, phosphoinositide 3-kinase; SD,
substrate domain.
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cancer. Consistent with this, p130Cas/BCAR1 has been
found commonly over-expressed in human TNBC [4].
Phosphoproteomic data from human breast cancer cell
lines have revealed that basal cancer cells exhibit higher
tyrosine phosphorylation of p130Cas/BCAR1 compared
with luminal cancer cells, despite similar p130Cas/BCAR1
expression in the two subgroups [44]. In line with this,
tyrosine phosphorylation of the p130Cas/BCAR1 SD
has emerged not only as a distinguishing feature of
ER-negative breast cancer cell lines compared with ER-
positive lines, but also crucial for the proliferation, migra-
tion and invasion of these cells [45] (Figure 3C).
Analysis of Nedd9 expression across different breast
cancers has revealed a correlation of this gene with the
TNBC subtype. TNBC cells require Nedd9 expression to
maintain their mesenchymal phenotype and to migrate
and invade in vitro [6]. Moreover, in contrast to ER-positive
cells, ER-negative breast cancer cells predominantly express
a hyper-phosphorylated form of Nedd9 (115 kDa Nedd9),
which represents the pool of Nedd9 able to sustain cell
adhesion and migration signalling [32].
Lastly, Nedd9 has been found over-expressed in clau-
din low breast cancers compared with other molecular
subtypes. In claudin low breast cancer cell lines TGF-beta
up-regulates Nedd9 expression by inducing Smad and
MRTF-SRF protein binding to regulatory regions within
the NEDD9 locus. Nedd9 induction is necessary to estab-
lish a positive feedback loop that integrates TGF-beta/
Smad and Rho-actin-SRF signalling and drives the expan-
sion of tumour-initiating cells, selectively in claudin low
breast cancer, upon TGF-beta stimulation [7] (Figure 3C).
p130Cas/BCAR1 and Nedd9 in anti-oestrogen
resistance
Tamoxifen is the most commonly used anti-oestrogen in
the treatment of breast cancer. Patients with ER-positive
breast tumours may initially benefit from this treatment,
but a significant proportion of these initially responding
patients acquire resistance to tamoxifen over time and
the disease progresses [46].
p130Cas/BCAR1 has been identified as a gene respon-
sible for the resistance to the anti-proliferative effects of
tamoxifen [29,47]. In general, in ER-positive breast cancer
patients, high levels of p130Cas/BCAR1 correlate with
earlier relapse and shorter overall survival [14].
A first hint as to the possible mechanisms underlying the
up-regulation of p130Cas/BCAR1 in tamoxifen-resistant
cells comes from the analysis of the BCAR1 gene pro-
moter. This study shows that BCAR1 gene transcription is
positively regulated by the transcription factor EGR1 and
its co-regulator NAB2. Importantly, the increased expres-
sion of NAB2 and the enhanced EGR1 binding to the
BCAR1 promoter observed in tamoxifen-resistant cells islikely to be responsible for the constitutive high expression
of p130Cas/BCAR1 [16].
Several mechanisms have been proposed to explain
the correlation between p130Cas/BCAR1 expression and
resistance to tamoxifen. A major determinant of the
p130Cas/BCAR1-dependent increased proliferation of
tamoxifen-resistant cells is the tyrosine phosphorylation
of the p130Cas/BCAR1 SD. Indeed, tyrosine phosphoryl-
ation of the p130Cas/BCAR1 SD is induced by tamoxifen
and correlates with tamoxifen-induced ER antagonist
effects [31]. Either silencing of p130Cas/BCAR1 or abro-
gation of p130Cas/BCAR1 signalling, by expressing a
dominant-negative tyrosine phosphorylated SD, is suffi-
cient to re-establish sensitivity to tamoxifen in resistant
cells. Inhibition of p130Cas attenuates the activation of
Erk1/2 and PI3K/Akt pathways and results in cell death in
response to tamoxifen [48].
Resistance to anti-oestrogen therapy specifically depends
on the substrate domain of p130Cas/BCAR1 and not of
Nedd9. Indeed, studies performed using chimeric proteins
containing defined domains of Nedd9 and p130Cas/BCAR1
indicate that differences in their substrate domains are
responsible for the differential effect on anti-oestrogen
resistance [49]. As the substrate domains of these two Cas
proteins differ in number, spacing and sequence context
of tyrosine motifs, a distinctive pattern of p130Cas/BCAR1
SD tyrosine phosphorylation may be responsible for the
recruitment of specific SH2 domain-containing proteins
and the subsequent assembly of molecular complexes
driving anti-oestrogen-resistant proliferation.
An additional mechanism implicated in tamoxifen
resistance relies on the interaction between p130Cas/
BCAR1 and the SH2-containing protein AND-34/
BCAR3. Although there is a clear correlation between
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and the association of BCAR3 with p130Cas/BCAR1, the
available data on the functional meaning of this inter-
action appear controversial [50]. However, it has been
recently demonstrated that the binding of BCAR3 to
p130Cas/BCAR1 increases the levels of phosphorylated
p130Cas/BCAR1, ultimately potentiating Erk1/2 phosphor-
ylation and sustaining BCAR1-dependent anti-oestrogen
resistance [51] (Figure 4).
Conclusion
p130Cas/BCAR1 and Nedd9, two members of the Cas
protein family, play a key role at multiple steps of mam-
mary tumourigenesis. Abnormal expression and/or phos-
phorylation of these two scaffold proteins leads to the
disruption of regulatory signalling circuits controlling
mammary cell survival, differentiation, proliferation and
migration.
Noteworthy, in spite of their structural similarity,
p130Cas/BCAR1 and Nedd9 exert both redundant and
specific functions in breast cancer cells. Although the func-
tional role of these two proteins has been extensively stud-
ied, further investigations are required to fully understand
the molecular mechanisms underlying the deregulation of
their expression in cancer. Moreover, high-resolution map-
ping of the interactions between Cas proteins and their
pro-growth/pro-migratory binding partners may provide a
rationale for the design of novel targeted therapies. Never-
theless, the use of Cas proteins as biomarkers for cancer
prognosis and drug responsiveness may improve the
clinical management of breast cancer.
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